Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial
05:02am, Wednesday, 18'th Mar 2026
OKYO Pharma Ltd (NASDAQ:OKYO) said on Wednesday it observed improvements in quality-of-life measures in patients treated with its experimental therapy...
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of “Hold” from Analysts
02:24am, Tuesday, 17'th Mar 2026
Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ: OKYO - Get Free Report) have received a consensus rating of "Hold" from the five analysts that are covering the firm, Marketbeat.com reports. One a
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
12:01pm, Monday, 23'rd Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye diseases, announced that its abstract has been ac
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026
11:56am, Monday, 23'rd Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain (NCP) and inflammatory eye...
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
11:00am, Monday, 23'rd Feb 2026
LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
12:59pm, Tuesday, 17'th Feb 2026
Analysts from Lucid Capital, H.C. Wainwright, and B.
OKYO Pharma has analysts bullish as FDA endorses Phase 2b/3 trial in neuropathic corneal pain
07:56am, Tuesday, 17'th Feb 2026
Analysts from Lucid Capital, H.C. Wainwright, and B. Riley Securities have all repeated ‘Buy’ ratings on OKYO Pharma Ltd (NASDAQ:OKYO), highlighting the...
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
09:11am, Friday, 13'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds of about $20 million. The clinical-stage bi
OKYO Pharma prices $20M offering to fund late-stage eye drug trial
03:50am, Friday, 13'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) has unveiled an underwritten public offering of around 10.8 million ordinary shares at $1.85 per share, raising gross proceeds...
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
10:20pm, Thursday, 12'th Feb 2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat
OKYO Pharma Announces Public Offering of Ordinary Shares
04:01pm, Thursday, 12'th Feb 2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
11:17am, Wednesday, 11'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases, announced that it has transitioned its At-The-
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
10:09am, Wednesday, 11'th Feb 2026
LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropa
Shopify shares slide despite Q4 revenue and EPS beat
07:22am, Wednesday, 11'th Feb 2026
Shopify Inc (TSX:SH., NYSE:SHOP) shares were down nearly 13% on Wednesday, even as the e-commerce platform reported fourth-quarter revenue and earnings per...
OKYO Pharma appoints Leerink Partners as sales agent for ATM equity offering
06:03am, Wednesday, 11'th Feb 2026
OKYO Pharma Ltd (NASDAQ:OKYO) a clinical-stage biopharmaceutical company focused on therapies for neuropathic corneal pain and inflammatory eye diseases,...
